Methods for enhancing wound healing
AssigneeMayo Foundation for Medical Education and Research, a Minnesota corporation
InventorsHolger Gassner, David Sherris
Life of this patent
Estimating the term…
Abstract
Abstract of the Disclosure A method for treating a patient having a wound is described. The method includes administering an amount of a chemodenervating agent such that healing of the wound is enhanced. The method is illustrated by detailing the mean differences of the scores of the paired experimental and control scars across three observers.
Claims35
1-31. (canceled) .
32. A method for treating a patient having a traumatic or an iatrogenic skin wound, said method comprising locally administering an amount of botulinum toxin to said skin wound, such that healing of said skin wound is enhanced.
33. The method of claim 32, wherein said botulinum toxin is selected from the group consisting of botulinum toxin A, B, C, D, E, F, and G.
34. The method of claim 33, wherein said botulinum toxin is botulinum toxin A.
35. The method of claim 33, wherein said botulinum toxin is botulinum toxin B.
36. The method of claim 32, wherein said administering step is by injection.
37. The method of claim 36, wherein said botulinum toxin is subcutaneously injected.
38. The method of claim 36, wherein said botulinum toxin is intramuscularly injected.
39. The method of claim 36, wherein said botulinum toxin is percutaneously instilled.
40. The method of claim 32, said method further comprising administering a local anesthetic.
41. The method of claim 40, wherein said local anesthetic is lidocaine.
42. The method of claim 40, wherein said local anesthetic is bupivacaine.
43. The method of claim 40, wherein said local anesthetic is mepivacaine.
44. The method of claim 40, wherein said local anesthetic is administered prior to administration of said botilinum toxin.
45. The method of claim 40, wherein said botulinum toxin and local anesthetic are co-administered.
46. The method of claim 32, said method further comprising administering a local vasoconstrictive agent.
48. The method of claim 46, wherein said local vasoconstrictive agent is epinephrine.
49. The method of claim 32, said method further comprising administering a local anesthetic and a local vasoconstrictive agent.
50. The method of claim 49, wherein said local anesthetic and said local vasoconstrictive agent are administered prior to said botulinum toxin.
51. The method of claim 32, wherein said skin wound is a facial wound.
52. The method of claim 32, wherein said skin wound is a surgically introduced incision.
53. The method of claim 52, wherein said botulinum toxin is administered prior to making said surgically introduced incision.
54. The method of claim 52, wherein said botulinum toxin is administered while making said surgically introduced incision.
55. The method of claim 52, wherein said botulinum toxin is administered after said surgically introduced incision has been made.
56. The method of claim 51, wherein said botulinum toxin is administered so as to not compromise eyelid closure.
57. The method of claim 32, wherein said skin wound is a favorable wound.
58. The method of claim 32, wherein said skin wound is an unfavorable wound.
59. The method of claim 32, wherein said skin wound comprises subcutaneous tissue.
60. The method of claim 32, wherein said skin wound is a head wound.
61. The method of claim 60, wherein said head wound is a forehead wound.
62. The method of claim 60, wherein said botulinum toxin is administered to said head wound so as to not compromise eyelid closure.
63. The method of claim 32, wherein said local administration comprises administration in or in close proximity to said skin wound.
66. The method of claim 51 or 60, wherein said botulinum toxin is administered so as to not compromise extraocular muscle movement.
Dependencies are inferred from the claim text.